Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug.
Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.
Company News for Dec 15, 2021
by Zacks Equity Research
Companies In The News Are: TSLA, TMX, NEOG, MMM, PFE.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Company News for Dec 14, 2021
by Zacks Equity Research
Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.
Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?
by Kinjel Shah
The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
by Zacks Equity Research
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
Pfizer (PFE) Gets Approval for New Eczema Drug in Europe
by Zacks Equity Research
Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.
Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.
J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation
by Zacks Equity Research
An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
ETFs to Play the Reopening Trade as Omicron Fear Subsides
by Sweta Jaiswal, FRM
The improved market sentiments have been leading to greater attention and confidence in reopening trades.
Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.
Stock Market News for Dec 9, 2021
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $51.40 in the latest trading session, marking a -0.62% move from the prior day.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study
by Zacks Equity Research
AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
by Zacks Equity Research
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.